RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
54 hedge funds and large institutions have $443M invested in RAPT Therapeutics in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 4 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 4
400% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 4
79% more capital invested
Capital invested by funds: $248M → $443M (+$195M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more funds holding
Funds holding: 38 → 54 (+16)
1.71% more ownership
Funds ownership: 6% → 7.71% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ROTUOC
Regents of the University of California
Oakland,
California
|
+$30.4M |
| 2 |
BlackRock
New York
|
+$11.7M |
| 3 |
Squarepoint
New York
|
+$3.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.42M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LM
Luminus Management
Houston,
Texas
|
-$5.68M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$1.66M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$295K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$213K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$178K |
RAPT Hedge Fund Activity: Q2 2020 in Review
54 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2020, worth a combined $443M — up 79% from $248M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RAPT positions and 4 closed out — a net gain of 16 holders — while 24 added to existing stakes and 4 trimmed.
The largest buyer was Regents of the University of California, opening a new position worth an estimated $30.4M. The largest seller was Luminus Management, exiting entirely with an estimated $5.68M sold.
- 54 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2020, up from 38 in Q1 2020.
- Funds reported $443M of RAPT Therapeutics stock for Q2 2020, up 79% quarter-over-quarter.
- 20 funds opened new RAPT Therapeutics positions in Q2 2020 and 4 closed out, a net change of +16 holders.
- The largest RAPT Therapeutics buyer in Q2 2020 was Regents of the University of California, an estimated $30.4M added.
- The largest RAPT Therapeutics seller in Q2 2020 was Luminus Management, an estimated $5.68M sold.
Based on aggregated 13F filings for Q2 2020.